 Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia CLL patients regardless of Brutons tyrosine kinase BTK mutational status BTK mutations conferring resistance to both covalent and non-covalent BTK inhibitors remain susceptible to degradation by NX-2127 Nurix will host a Key Opinion Leader KOL webcast event at 9:30 pm ET today ... The post Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader NX-2... 